Verflixt! Es sieht so aus, als wenn Sie einen veralteten Browser benutzen. Wir empfehlen Ihnen dringend Ihren Browser zu aktualisieren.
Weitere Informationen über Browser und Updates finden Sie hier

Bavarian Nordic GmbH

Bavarian Nordic is a vaccine-focused biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need.

The company's pipeline targets cancer and infectious diseases and includes ten development programs. In oncology, the company's lead program is PROSTVAC®, a therapeutic vaccine candidate for advanced prostate cancer that is the subject of an ongoing pivotal Phase 3 trial and is being developed under a collaboration agreement with the National Cancer Institute. In infectious diseases, the company's lead program is IMVAMUNE®, a third-generation smallpox vaccine candidate that is being developed and supplied for emergency use to the U.S. Strategic National Stockpile under a contract with the U.S. Government.

Details


Adresse:
Bavarian Nordic GmbH

Fraunhoferstrasse 13
82152 Martinsried
Deutschland
Arbeitsgebiet:
Sonstige Tätigkeitsfelder
Expansion:
national
Mitarbeiteranzahl:
51-500
Gründungsjahr:
1994